This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (February 2017) (Learn how and when to remove this template message)
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "AryoGen" – news · newspapers · books · scholar · JSTOR (February 2017) (Learn how and when to remove this template message)
(Learn how and when to remove this template message)
 | |
| Company type | Private Company |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2009 |
| Headquarters | , |
Area served | Worldwide |
Key people | Fereidoun Mahboudi Chairman |
| Products | biopharmaceuticals, Monoclonal antibody |
| Revenue |  US$ 100 million |
Number of employees | 300+ (2015) |
| Website | AryoGen |
AryoGen Pharmed (Persian: آریوژن فارمد) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]
